Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus QUADRAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus QUADRAMET.
MACROTEC vs QUADRAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical